PP_1170x120_10-25-21

generic version of Xopenex

Aurobindo cleared to market generic Xopenex

Aurobindo cleared to market generic Xopenex

EAST WINDSOR, N.J. — Aurobindo Pharma Ltd. has gained final approval from the Food and Drug Administration for levalbuterol inhalation solution in dosages of 0.31 mg/3 ml, 0.63 mg/3 ml and 1.25 mg/3 ml. The medication is used to treat breathing problems in patients with conditions such as asthma or chronic obstructive pulmonary disease (COPD).